2026-04-29T10:47:13Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/179362024-09-21T22:34:52Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927

00925njm 22002777a 4500 dc Comi, Giancarlo author Alroughani, Raed author Boster, Aaron L author Bass, Ann D author Berkovich, Regina author Fernández, Óscar author Kim, Ho Jin author Limmroth, Volker author Lycke, Jan author Macdonell, Richard Al author Sharrack, Basil author Singer, Barry A author Vermersch, Patrick author Wiendl, Heinz author Ziemssen, Tjalf author Jacobs, Alan author Daizadeh, Nadia author Rodriguez, Claudio E author Traboulsee, Anthony author CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ Investigators author 2019-11-25 Alemtuzumab is given as two annual courses. Patients with continued disease activity may receive as-needed additional courses. To evaluate efficacy and safety of additional alemtuzumab courses in the CARE-MS (Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis) studies and their extensions. Subgroups were based on the number of additional alemtuzumab courses received. Exclusion criteria: other disease-modifying therapy (DMT); In the additional-courses groups, Courses 3 and 4 reduced annualized relapse rate (12 months before: 0.73 and 0.74, respectively; 12 months after: 0.07 and 0.08). For 36 months after Courses 3 and 4, 89% and 92% of patients were free of 6-month confirmed disability worsening, respectively, with 20% and 26% achieving 6-month confirmed disability improvement. Freedom from magnetic resonance imaging (MRI) disease activity increased after Courses 3 and 4 (12 months before: 43% and 53%, respectively; 12 months after: 73% and 74%). Safety was similar across groups; serious events occurred irrespective of the number of courses. Additional alemtuzumab courses significantly improved outcomes, without increased safety risks, in CARE-MS patients with continued disease activity after Course 2. How this compares to outcomes if treatment is switched to another DMT instead remains unknown. http://hdl.handle.net/10668/14739 http://hdl.handle.net/20.500.12105/17936 31762387 10.1177/1352458519888610 1477-0970 Multiple sclerosis (Houndmills, Basingstoke, England) Alemtuzumab Efficacy Multiple sclerosis Relapse Retreatment safety Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies.